ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Consensus Price Target of $7.60 According to AnalystsDefense World · Oct 18, 2026
ProQR Reports First Human Validation of RNA Editing Platform in Liver DiseaseMarketBeat · Oct 2, 2026
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call TranscriptSeeking Alpha · Sep 30, 2026
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI AdvisorGlobeNewsWire · Sep 23, 2026
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026GlobeNewsWire · Sep 9, 2026
ProQR to Participate in Upcoming Investor Conferences in September 2026GlobeNewsWire · Sep 2, 2026ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.13 | -$0.10 | Beat |
| May 12, 2026 | -$0.15 | -$0.15 | Beat |
| Mar 12, 2026 | -$0.08 | -$0.09 | Miss |
| Nov 6, 2025 | -$0.10 | -$0.12 | Miss |
| Aug 7, 2025 | -$0.08 | -$0.14 | Miss |
| May 8, 2025 | -$0.09 | -$0.11 | Miss |